全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 251456-60-7 |
|---|---|---|---|
| 分子式 | C16H25N3O3 | 纯度 | 98% |
| 分子量 | 307.39 | 货号 | abs47027919 |
| 规格 | 2mg | 供货周期 | 现货 |
| 主要用途 | is a potent HDAC | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
M344 251456-60-7
| 产品描述 | |
| 描述 | M344 is a potent HDAC inhibitor with IC50 of 100 nM and able to induce cell differentiation. |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | Histone Deacetylase Inhibitor III |
| 外观 | 白色至淡黄色粉末 |
| 可溶性/溶解性 | Ethanol ：4 mg/mL (13.01 mM) DMSO ：62 mg/mL (201.69 mM) |
| 生物活性 | |
| 靶点 | HDAC |
| In vitro(体外研究) | M344 is a potential histone deacetylase (HDAC) inhibitor. BRCA1 mRNA levels are determined by RT-PCR following exposure to increasing concentrations of the HDAC inhibitor M344 alone and in combination with Cisplatin in all 6 cell lines evaluated in this study. With increasing concentrations of M344, there is a dose dependant decrease in BRCA1 mRNA and treatment with both 1 and 5 μM concentrations of M344 resulting in a significant decrease in BRCA1 expression in all cell lines examined. M344 in combination with Cisplatin leads to a decrease in BRCA1 mRNA expression as compared to Cisplatin treatment alone in all cell lines with the exception of A2780s, which is recognized as having potent cytotoxicity to Cisplatin. In the MCF7 cell line, BRCA1 is down regulated at physiological doses of M344 (0.5 μM and 1 μM) but M344 does not have the same inhibitory effect on BRCA1 at the 5.0 μM dose. Co-treatment with Cisplatin and increasing concentrations of M344 reduces BRCA1 protein levels in all breast and ovarian cell lines examined. |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | CancerCancer Metabolism CancerTumor biomarkers Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：